A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Trial details
- Registry ID
- NCT06346067
- Phase
- Phase 3
The FDA approved Trametinib (Mekinist) on 29 May 2013.
Drug identity checked against registry records
Also recorded as Mekinist
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)NCT06346067 | ERAS | Phase 3 | Active not recruiting | 2028-04Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2013-05-29Day | Trametinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA204114", "applicant_as_listed_by_fda": "NOVARTIS", "brand_names": ["MEKINIST"], "active_ingredients": ["TRAMETINIB DIMETHYL SULFOXIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20130529", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |